Published in Hepatitis Weekly, December 2nd, 2002
Researchers across the world are presently evaluating consensus interferon (CIFN) for use as monotherapy or in combination with ribavirin as a treatment for chronic hepatitis C. Interferon therapy is linked to the evolution of thrombocytopenia, or low platelet counts in the serum of patients infected with hepatitis C virus (HCV). Even so, medical investigators in Taiwan have announced changes in platelet counts and serum thrombopoietin levels are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.